Merck was dealt a blow toward the end of December after one of its cholesterol drugs, called Tredaptive, failed its outcomes study. It looks like the pharma stalwart won't seek approval from the Food and Drug Administration for this drug, but it hasn't given up on this market just yet. The company announced yesterday that the FDA will review its other cholesterol-fighter, which is a combination of the drugs ezetimibe and atorvastatin.
This therapeutic was already denied approval back in March -- but will additional data give Merck the green light this time around? What other drugs should Merck investors be watching in 2013?
Health care analyst Max Macaluso tackles these questions in the following video.
What's inside Supernova?
If you're an investor looking for big long term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article Will More Data Make the Difference for Merck? originally appeared on Fool.com.
Max Macaluso, Ph.D. and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.